secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2023-03-22T23:59:59+00:00
Accession:  0000950170-23-009162
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics reports FY2022 net loss $63.3M; cash $98.5M; RT-102 Phase 2 in H2 2023
--------------------------------------------------------------------------------

- Net loss $63.3M for 2022, vs $53.1M in 2021; cash $98.5M, sufficient to mid-2024.
- Phase 1 data for RT-102 (osteoporosis) positive; FDA agrees 505(b)(2) pathway; Phase 2 planned H2 2023.
- Partnership with Celltrion for RT-111 (ustekinumab biosimilar); exclusive license with right of first negotiation.
- Expects to start three Phase 1 studies in 2023 for RT-105, RT-110, RT-111.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000095017023009162/0000950170-23-009162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000095017023009162/rani-20230322.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-009162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer